Limertinib

An inhibitor of mutant EGFR, selective for EGFRL858R/T790M, EGFRT790M, and EGFR containing an exon 19 deletion (IC50s = 0.3, 0.5, and 0.5 nM, respectively) over wild-type EGFR (IC50 = 6 nM) and a panel of 258 kinases at 100 nM, inhibits BTK and Itk (IC50s = 2.1 and 0.4 nM, respectively), selectively inhibits the proliferation of H1975, PC-9, and HCC827 cancer cells, which express mutant EGFRs (IC50s = 12, 6, and 2 nM, respectively), over A431, LoVo, and A549 cancer cells, which express wild-type EGFR (IC50s = 388, 1,916, and 1,541 nM, respectively), induces tumor regression in an H1975 NSCLC mouse xenograft model at 1 mg/kg. SMILES: O=C(NC1=CC(NC2=NC=C(C(NC3=CC4=C(C=CC=C4)C=C3)=N2)Cl)=C(C=C1N(CCN(C)C)C)OC)C=C. InChi Code: InChI=1S/C29H32ClN7O2/c1-6-27(38)33-23-16-24(26(39-5)17-25(23)37(4)14-13-36(2)3)34-29-31-18-22(30)28(35-29)32-21-12-11-19-9-7-8-10-20(19)15-21/h6-12,15-18H,1,13-14H2,2-5H3,(H,33,38)(H2,31,32,34,35). InChi Key: QHPVTCLSVVUPOF-UHFFFAOYSA-N